Authors: Carol Lynch and Erin Federman
Could you tell us what the key focuses for the Biosimilar Medicines Group, a Medicines for Europe sector group, are at present?
Biosimilar medicines bring competition to the biologics market, which in turn creates broader access for patients and supports the best use of available resources and sustainability of the European healthcare system.
Over the last decade, we have seen the range of available biosimilar medicines evolve and grow to cover even more therapeutic areas. This demonstrates the important role biosimilar medicines play in sustainable healthcare, particularly as more individuals with chronic diseases live longer and critical innovative therapies come to market, adding an even greater cost burden to an already strained system.
The movement in the biosimilar medicines industry is due in part to: